Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching new highs. Markets fell following the President’s announcement of unexpectedly severe tariffs, which raised recession fears. After a brief pause on tariffs, markets regained confidence, closing the quarter at or near all-time highs. In this environment, the Baird Chautauqua International Growth Fund underperformed its benchmark during the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, Baird Chautauqua International and Global Growth Fund highlighted stocks such as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The one-month return of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was -2.89%, and its shares lost 46.36% of their value over the last 52 weeks. On September 26, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock closed at $563.90 per share, with a market capitalization of $59.766 billion.

Baird Chautauqua International and Global Growth Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its second quarter 2025 investor letter:

“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported mixed top-line results from a pipeline drug, itepekimab, in Chronic Obstructive Pulmonary Disease (COPD), with one of the two trials meeting expectations. While itepekimab is not expected to be a core driver of Regeneron’s shares, other drug candidates in its pipeline continue to advance.”

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 73 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the second quarter, up from 66 in the previous quarter. In the second quarter of 2025, Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) total revenues reached $3.7 billion, which represents a 4% growth compared to the previous year. While we acknowledge the risk and potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and shared the list of most undervalued NASDAQ stocks to buy. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.